The Latest Breaking News from Novavax

Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government's vaccine rollouts told Reuters.

The first shipment of Novavax touches down in Australia ahead of the rollout later this month, but there are a few more steps involved before it gets to vaccine clinics.

Here's your TL;DR for this morning's news.

Germany's expert panel on vaccine use has recommended Novavax Inc's (NASDAQ:

The jab, made by manufacturer Novavax, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) after safety, quality and effectiveness tests

Nuvaxovid is similar to flu jab and may have reduced side-effects, which could persuade vaccine holdouts

Europe could enter ‘long period of Covid tranquility’ due to high vaccination rates, WHO says; record 1.33 million UK long Covid patients

A whale with a lot of money to spend has taken a noticeably bearish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 14 strange trades.

WASHINGTON — Moderna Inc.’s vaccine for COVID-19 received full approval from the U.S. Food and Drug Administration for people 18 and older, an important milestone that bolsters the shot’s use as a major weapon against the virus.

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. Novavax was up 13% at $93.70 Monday afternoon at publication.

Novavax Inc (NASDAQ: NVAX) is trading higher Monday after the company submitted a request to the U.S Food and Drug Administration for Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373.